Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:04 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,567 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Regimen Clear all
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06603077
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
AVTX-009 Regimen 1, AVTX-009 Regimen 2, Placebo
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
36
States / cities
Scottsdale, Arizona • Tucson, Arizona • Northridge, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Nov 1, 2026, 5:04 PM EST
Terminated Phase 4 Interventional

Enteral Naloxone Versus a Traditional Bowel Regimen for the Prevention of Opioid Induced Constipation in Trauma Patients

NCT00799201
View directory record Official record
Conditions
Constipation, Analgesia
Interventions
Naloxone and Docusate
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Nov 1, 2026, 5:04 PM EST
Not yet recruiting Phase 4 Interventional

Examining Analgesic Synergy and Efficacy in Trauma Care

NCT07435077
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, Oxycodone
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 1, 2026, 5:04 PM EST
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy

NCT00688701
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Nov 1, 2026, 5:04 PM EST
Terminated Phase 3 Interventional

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

NCT00057343
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Zevalin (ibritumomab tiuxetan), Rituxan (rituximab)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
67
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2006 · Synced Nov 1, 2026, 5:04 PM EST
Withdrawn Phase 2 Interventional

EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis

NCT06646016
View directory record Official record
Conditions
Immune-related Colitis
Interventions
Methoxsalen, Infliximab, Vedolizumab
Drug
Lead sponsor
Therakos LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Nov 1, 2026, 5:04 PM EST
Completed Not applicable Interventional Results available

Technology Intensified Diabetes Education Study in African Americans

NCT02088658
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Type II
Interventions
Technology Intensified
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
21 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Nov 1, 2026, 5:04 PM EST
Completed Phase 4 Interventional Results available

Minimal Opioid Use After Total Hip Replacement (THR)

NCT03090152
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Periarticular injection (Deep injection), Periarticular injection (Superficial injection), Bupivacaine, Placebo
Procedure · Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Nov 1, 2026, 5:04 PM EST
Terminated Not applicable Interventional

Auricular Acupuncture to Facilitate Outpatient Opioid Weaning

NCT02882048
View directory record Official record
Conditions
Narcotic Addiction
Interventions
NADA Protocol, Medication management
Procedure · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Nov 1, 2026, 5:04 PM EST
Terminated Phase 3 Interventional Results available

Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

NCT00920582
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Teplizumab Herold Regimen, Placebo, Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
8 Years to 35 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
42
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Nov 1, 2026, 5:04 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT

NCT06149403
View directory record Official record
Conditions
MPS-IH (Hurler Syndrome)
Interventions
Experimental: OTL-203, Active Comparator: Allo-HSCT
Genetic
Lead sponsor
Orchard Therapeutics
Industry
Eligibility
28 Days to 30 Months
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Nov 1, 2026, 5:04 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

NCT02935686
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant, Placebo, gp140 HIV Bivalent Vaccine
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Nov 1, 2026, 5:04 PM EST
Recruiting Phase 2 Interventional

A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months

NCT07126262
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Vosoritide, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
0 Months to 36 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 1, 2026, 5:04 PM EST
Completed Phase 3 Interventional

Phase 3 Study to Compare the Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media

NCT02044341
View directory record Official record
Conditions
Acute Otitis Media
Interventions
AR01, Glycerin ear drops
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
2 Months to 18 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
29
States / cities
Sheffield, Alabama • Tuscon, Arizona • Jonesboro, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Nov 1, 2026, 5:04 PM EST
Terminated Phase 2 Interventional

Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia

NCT01081964
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
Zabofloxacin, Levofloxacin 500mg, Zabofloxacin 400mg
Drug
Lead sponsor
IASO Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
13
States / cities
Huntsville, Alabama • Toney, Alabama • Fort Myers, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Nov 1, 2026, 5:04 PM EST
Recruiting Phase 3 Interventional

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

NCT07625644
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
Interventions
BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
Springdale, Arkansas • Glendale, California • Long Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 1, 2026, 5:04 PM EST
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity

NCT00878592
View directory record Official record
Conditions
Post Liver Transplantation Weight Gain, Post Liver Transplantation Obesity, Nonalcoholic Steatohepatitis
Interventions
Dietary and life style modification
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Nov 1, 2026, 5:04 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

NCT01767311
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
91
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 1, 2026, 5:04 PM EST
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Sprix for Postoperative Pain Control Following Gynecologic Surgery

NCT04444830
View directory record Official record
Conditions
Post Operative Pain Control, Narcotic Use, Pelvic Organ Prolapse, Urinary Incontinence , Stress, Surgery
Interventions
Sprix
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Nov 1, 2026, 5:04 PM EST
Completed Not applicable Interventional Results available

Northwestern University and Access Community Health Network Medication Education Study

NCT01578577
View directory record Official record
Conditions
Hypertension
Interventions
EHMI, Nurse Educator + EHMI
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Nov 1, 2026, 5:04 PM EST
Terminated Phase 2 Interventional Results available

Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus

NCT02935673
View directory record Official record
Conditions
Respiratory Syncytial Viruses
Interventions
lumicitabine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Fresno, California • Orange, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Nov 1, 2026, 5:04 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging

NCT03818802
View directory record Official record
Conditions
Healthy Elderly Volunteers
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years to 80 Years · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Nov 1, 2026, 5:04 PM EST
Completed Not applicable Interventional

A Six Month Randomized Controlled Clinical Trial of Lung Flute in Patients With Chronic Obstructive Pulmonary Disease

NCT01186822
View directory record Official record
Conditions
COPD
Interventions
Lung Flute
Device
Lead sponsor
Nicolaas J Smit PhD
Industry
Eligibility
30 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2015 · Synced Nov 1, 2026, 5:04 PM EST
Active, not recruiting Not applicable Interventional Results available

Pharmacist Intervention to Reduce Post-Hospitalization Utilization

NCT04071951
View directory record Official record
Conditions
Nonadherence, Patient, Polypharmacy, Readmission
Interventions
Pharmacist-led Hospital Discharge Care Intervention
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
55 Years and older
Enrollment
6,478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Nov 1, 2026, 5:04 PM EST